Home › Search
Search
439 results for "lecanemab".
Research summaries 393
Showing the best 200 of 393, 171–180, page 18 of 20. Filter these by subject, year and score in the research library →
-
Lecanemab binds to transgenic mouse model-derived amyloid-β fibril structures resembling Alzheimer’s disease type-I, type-II and Arctic foldsResearch summary
Research summaries · alzhub.org/study/lecanemab-binds-to-transgenic-mouse-model-derived-amyloid-fibril-c94ba780
Lecanemab, an Alzheimer’s disease US Food and Drug Administration approved monoclonal antibody was previously reported to have a high affinity against intermediately sized amyloid-β aggregates. Subsequently, it was observed by …
-
Amyloid and Tau Cerebrospinal Fluid Biomarker Normalization in a Patient with Alzheimer’s Disease treated with Lecanemab: A Case ReportResearch summary
Research summaries · alzhub.org/study/amyloid-and-tau-cerebrospinal-fluid-biomarker-normalization-in-a-1d9e787e
… biomarkers following lecanemab therapy in a patient with Alzheimer’s disease (AD). Methods A woman (APOEε3/ε4) was diagnosed with AD after clinical, neurocognitive, and CSF evaluation. She received 10mg/kg of intravenous …
-
Characterizing clinician communication with patients about lecanemab: A qualitative study of clinicians across seven academic medical centersResearch summary
Research summaries · alzhub.org/study/characterizing-clinician-communication-with-patients-about-lecanemab-40873665
Introduction Anti-amyloid monoclonal antibodies (mAbs) slow cognitive decline in Alzheimer's disease but may cause amyloid-related imaging abnormalities (ARIA), which can rarely be disabling or fatal. This qualitative study …
-
Recalibrating the Risk-Benefit Profiles of Lecanemab and Donanemab: Scales, Immunoreactivity, and Changes in Amyloid-β42Research summary
Research summaries · alzhub.org/study/recalibrating-the-risk-benefit-profiles-of-lecanemab-and-donanemab-38701151
Three recent anti-amyloid-β antibody trials for Alzheimer's disease reported similar effect sizes, used non-reactive saline as placebo, and showed large numbers of adverse events including imaging anomalies (ARIA) that correlate …
-
Research summaries · alzhub.org/study/the-efficacy-and-safety-of-anti-amyloid-monoclonal-antibody-versus-40316479
… non-carriers. Finally, lecanemab demonstrated relatively better efficacy and a more favorable profile on ARIA-E compared to aducanumab and donanemab. Conclusions mABs were associated with a slower progression of cognitive decline …
-
Research summaries · alzhub.org/study/attitudes-of-specialist-memory-clinic-patients-with-early-symptomatic-42426158
Before answering four binary questions, participants received brief explanatory information on expected clinical benefit, amyloid-related imaging abnormalities (ARIA), and the increased ARIA risk associated with APOE ε4 …
-
Multiple Ischemic Strokes in a Patient Treated with Lecanemab: A Case ReportResearch summary
Research summaries · alzhub.org/study/multiple-ischemic-strokes-in-a-patient-treated-with-lecanemab-a-case-77a96126
… amyloid-lowering drug lecanemab who developed both ARIA-H and ARIA-E, and multiple ischemic infarctions. Conclusion This finding, in conjunction with previous reports of ischemic infarction in the setting of anti-amyloid therapy, …
-
Racial and ethnic differences in plasma p-tau217 ratio biomarker eligibility rates in a preclinical AD trial with lecanemabResearch summary
Research summaries · alzhub.org/study/racial-and-ethnic-differences-in-plasma-p-tau217-ratio-biomarker-40861822
Among 6437 participants screened, with non-Hispanic (NH) White as the reference group, odds ratios of plasma ineligibility were 2.88 (95% confidence interval [CI]: 1.40-6.96) for Hispanic Black, 1.60 (95% CI: 1.33-1.92) for …
-
Anti-Amyloid Antibodies in the Treatment of Alzheimer's Disease: An Umbrella ReviewResearch summary
Research summaries · alzhub.org/study/anti-amyloid-antibodies-in-the-treatment-of-alzheimer-s-disease-an-42739787
… Patients treated with lecanemab or donanemab showed statistically significant changes on cognitive scales such as the Clinical Dementia Rating-Sum of Boxes (CDR-SB) (mean effect estimate -0.485, SD = 0.152, -0.70 to -0.34) and …
-
Comparisons of efficacy and safety of immunotherapies for Alzheimer's disease treatment: A network meta-analysis of randomised controlled trialsResearch summary
Research summaries · alzhub.org/study/comparisons-of-efficacy-and-safety-of-immunotherapies-for-alzheimer-s-40473116
Fifty-nine RCTs were included. Donanemab and lecanemab ranked among the most effective treatments for improving cognitive function (Clinical Dementia Rating Scale - Sum of Boxes P-scores: 0.88 and 0.77) and daily activities …
How this search works
There is no outside search company involved. The site builds its own index by reading its own pages — the same words you would see on the page — and each result shows a literal snippet of that text with your words highlighted. Nothing is summarised or rewritten by a machine in between.
One addition, made by hand: a short list of everyday words that our pages cover under another name. Search "symptoms" and you are also shown The 10 warning signs; "medication" leads to Treatments & medicines; "hotline" to the helplines. A result reached that way shows the page's own description, and it only ever points to a page that already covers the subject.
31503 pages, questions, glossary terms and research summaries are indexed, last rebuilt 2026-11-13. Las páginas en español también aparecen en estos resultados. The clinical trial records are not in this index — they have their own finder, which searches all trial titles, sponsors and drugs directly.